Advertisement

Topics

KEYNOTE-189: Chemo + Immunotherapy Now Viable for PD-L1 Low NSCLC

08:13 EDT 17 May 2018 | Medscape

While KEYNOTE-189 answered many questions about immuno-oncology for NSCLC, Drs West and Borghaei look forward to results of KEYNOTE-042 for even more answers.
Medscape Oncology

Original Article: KEYNOTE-189: Chemo + Immunotherapy Now Viable for PD-L1 Low NSCLC

NEXT ARTICLE

More From BioPortfolio on "KEYNOTE-189: Chemo + Immunotherapy Now Viable for PD-L1 Low NSCLC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...